British-American multinational pharmaceutical company, GlaxoSmithKline plc’s antibody treatment sotrovimab is said to be effective against all 37 types of Omicron. A single intravenous injection results in a less than threefold drop in neutralization. Based on the findings of the study, the company said that sotrovimab may cause fewer symptoms and reduce the risk of serious consequences of COVID-19. Antibody medicine is given by a health care specialist within 10 days of initial infection to people over the age of 12. It is used only for mild or moderate cases. Sotrovimab is an FDA-approved emergency medicine used to treat patients who are at high risk of developing complications related to the coronavirus because of older age, obesity, or conditions such as lung, kidney, or heart disease, diabetes used for the treatment of
,